Compare EMBJ & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EMBJ | ABVX |
|---|---|---|
| Founded | 1969 | 2013 |
| Country | Brazil | France |
| Employees | N/A | 67 |
| Industry | Aerospace | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 10.5B |
| IPO Year | N/A | N/A |
| Metric | EMBJ | ABVX |
|---|---|---|
| Price | $72.43 | $121.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $128.42 |
| AVG Volume (30 Days) | ★ 790.9K | 707.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.36 | $0.22 |
| P/E Ratio | $159.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $59.73 | $4.77 |
| 52 Week High | $80.75 | $148.83 |
| Indicator | EMBJ | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 50.16 | 47.74 |
| Support Level | $68.91 | $107.99 |
| Resistance Level | $74.85 | $131.27 |
| Average True Range (ATR) | 1.87 | 4.74 |
| MACD | -0.12 | -0.19 |
| Stochastic Oscillator | 50.39 | 29.08 |
Embraer SA based in Sao Paulo, Brazil, manufacturer of jets. Its focus is to achieve customer satisfaction with and services addressing the commercial airline, executive jets, and defense and security markets. It has developed a customer-centric technology-driven portfolio of commercial aviation products and services that allows it to build long-term relationships with clients in the commercial aviation, executive jets, and defense and security markets. It operates through the various segments namely Commercial Aviation, Defense and Security, Executive Aviation, Service and Support, and Other Segments. The company generates maximum revenue from the Commercial Aviation segment.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.